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The aim of this study was to determine prognostic factors for the risk of new vascular events
during the first 6 months after acute myocardial infarction (AMI) or atherothrombotic stroke
(AS). We were interested in the prognostic role of endothelial progenitor cells (EPC) and cir-
culating endothelial cells (CEC)
Methods
Between February 2009 and July 2012, 100 AMI and 50 AS patients were consecutively
studied in three Spanish centres. Patients with previously documented coronary artery dis-
ease or ischemic strokes were excluded. Samples were collected within 24h of onset of
symptoms. EPC and CEC were studied using flow cytometry and categorized by quartiles.
Patients were followed for up to 6 months. NVE was defined as new acute coronary syn-
drome, transient ischemic attack (TIA), stroke, or any hospitalization or death from cardio-
vascular causes. The variables included in the analysis included: vascular risk factors,
carotid intima-media thickness (IMT), atherosclerotic burden and basal EPC and CEC
count. Multivariate survival analysis was performed using Cox regression analysis.
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Results
During follow-up, 19 patients (12.66%) had a new vascular event (5 strokes; 3 TIAs; 4 AMI;
6 hospitalizations; 1 death). Vascular events were associated with age (P = 0.039), carotid
IMT0.9 (P = 0.044), and EPC count (P = 0.041) in the univariate analysis. Multivariate Cox
regression analysis showed an independent association with EPC in the lowest quartile
(HR: 10.33, 95%CI (1.22–87.34), P = 0.032] and IMT0.9 [HR: 4.12, 95%CI (1.21–13.95),
P = 0.023].
Conclusions
Basal EPC and IMT0.9 can predict future vascular events in patients with AMI and AS, but
CEC count does not affect cardiovascular risk.
Introduction
Endothelial progenitor cells (EPC) are mobilized from bone marrow and participate in adult
neovascularization after both myocardial infarction [1] and ischemic stroke [2,3]. Circulating
endothelial cells (CEC) on the other hand are mature cells that have detached from the intimal
monolayer in response to endothelial injury [4]. Both types of cell are increased in patients
with acute vascular disease [4–6]. However, the total count of these cells may be influenced by
the presence of vascular risk factors traditionally associated with lower EPC and higher CEC
counts [7–10] and the effects of medication to control these risk factors [11]. To date, no stud-
ies have analysed these two cell subtypes together in the same population.
In patients with stable coronary artery disease (CAD), EPC count has been associated with
the risk of future cardiovascular events, mostly coronary revascularization [12,13]. However,
the influence of these cells after acute myocardial infarction (AMI) is less well known. A previ-
ous study found the level of circulating EPCs to be predictive of poor neurological status and
early stroke recurrence after ischemic stroke of various etiologies [14]. The role of CECs in
both conditions has not been established.
The PROCELL study was a multicentre, prospective, population-based, case-control study
paired by sex and age. The aim of the study was to compare the short- and long-term mobiliza-
tion of EPCs and CECs following an AMI or an atherothrombotic stroke (AS), as this type of
stroke shares the same etiology, large-vessel disease, and high cardiovascular risk of CAD
[15,16]. Controls were recruited from a population-based cross-sectional study (REGICOR
cohort study) [17], all free of selected cardiovascular risk factors (hypertension, dyslipidemia,
diabetes), and matched by age and sex with cases. The main findings of this study have recently
been published elsewhere [18]. In this substudy, we aimed to determine the effect of basal EPC
and CEC on the risk of new vascular events (NVE) among high-risk vascular patients.
Methods
The PROCELL study was a multicenter, prospective study performed in three tertiary hospital
centres in Spain. The study was conducted according to the principles expressed in the Decla-
ration of Helsinki. The study protocol was approved by the Institutional Ethics Committees
(Hospital del Mar, Barcelona; Hospital Clínic, Barcelona; Hospital Clínico Universitario de
Valencia) and all patients gave written informed consent before being included.
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Study population
Between February 2009 and July 2012, we included 100 consecutive patients with AMI—either
ST elevation myocardial infarction (STEMI) or non-ST elevation MI (NSTEMI)—and 50
patients with acute ischemic stroke or transient ischemic attack (TIA) of atherothrombotic ori-
gin according to SSS-TOAST criteria [19] (presence of plaques in the symptomatic intracranial
or extracranial artery with stenosis>50%, or stenosis<50% in a patient with more than one
traditional vascular risk factor after excluding other embolic sources).
Inclusion criteria for AMI patients were75 years of age, first AMI, and the presence of
more than one traditional vascular risk factor. Exclusion criteria were documented CAD and
previous treatment with statins. Inclusion criteria for AS were75 years of age and initial
stroke severity<20 on the National Institute of Health Stroke Scale (NIHSS). Exclusion criteria
were previous documented stroke, previous disability>2 on the modified Rankin scale (mRS),
and previous treatment with statins. We also excluded patients with kidney disease, active neo-
plasm, and chronic inflammatory or infectious diseases from both cohorts.
All patients underwent an initial arterial study that included a B-mode ultrasound of the
carotid and vertebral arteries and transcranial Doppler ultrasound to assess intracranial circu-
lation. A second arterial study confirmed the degree of stenosis, either by MRI angiogram
(n = 36) or CT angiogram (n = 14). Degree of stenosis was categorized into four groups: 30% to
50%; 51% to 70%; 71% to 99%; and complete occlusion.
All patients received treatment according to current guidelines.
Circulating endothelial cell and endothelial progenitor cell counts
Samples were collected in the first 24h after the initial AMI or AS. Blood was recovered in low
molecular weight heparin tubes and processed in duplicate within 4h of extraction. An assessment
of 2×106 events per sample was considered sufficient for statistical analysis. EPC were defined as
negative for CD45 and positive for CD34, KDR, and CD133 (CD45-CD34+KDR+CD133+). CEC
were defined as negative for CD45 and positive for CD146 and CD31 (CD45-CD146+CD31+).
We multiplied the EPC to CEC ratio obtained from flow cytometry analysis by the number of leu-
kocytes/ml in the blood sample to obtain the absolute number of each cell type per 1 mL of whole
blood.
Variables analysed
We recorded traditional cardiovascular risk factors for all patients according to standard defi-
nitions: age, sex, hypertension, diabetes, hypercholesterolemia, body mass index (BMI), admis-
sion lipids and HbA1c levels, and previous medication. Other variables recorded were:
common carotid artery (CCA) intima-media thickness (IMT), defined as the mean of three
measurements in each carotid artery and measured using a semi-automated carotid ultrasound
system (Sonosite MIcroMaxx IMT calc) according to international consensus [20]; and athero-
sclerotic burden (AB), determined on the basis of the number of affected vascular territories:
coronary, cerebrovascular, and peripheral [21]. For the AB evaluation, all patients had carotid
and transcranial Doppler ultrasounds (US). Cerebrovascular disease was diagnosed if>50%
stenosis was found in the supra-aortic ultrasound. In stroke patients, CAD was evaluated with
CT coronary angiography and diagnosed when stenosis exceeded 50%. Peripheral artery dis-
ease (PAD) was defined if the ankle-brachial index score was<0.9 or there was a previous his-
tory of intermittent claudication. Patients were thus classified into 3 groups according to the
presence of disease in each territory. All data were available except IMT, which was not mea-
surable in 17 patients (11.33%).
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Follow-up and vascular events
All patients had follow-up visits at 7, 30, 90, and 180 days. At each visit, any NVE was recorded.
The study endpoints included new acute coronary syndrome, any TIA or stroke, and any hos-
pitalization or death from cardiovascular causes. No patients were lost to follow-up.
Statistical methods
Means, standard deviations and frequencies were computed to describe continuous, normally
distributed, and categorical variables, respectively. Normality plots were constructed to check
whether continuous variables followed normal distributions. EPCs and CECs were categorized
into quartiles for further analysis. Student’s t-tests and ANOVA were performed to compare
means between 2 or more groups, respectively, while chi-square tests were computed to com-
pare frequencies between groups. Multivariate survival analysis was performed using Cox
regression models to estimate the hazard ratio (HR) for NVE with 95% confidence intervals
(CI). Multivariate models were adjusted for associated variables in the univariate analysis, con-
sidering a 2-sided P-value<0.05 as significant. Sensitivity analyses were performed to analyse
potential confounding variables, due to the known association between age and a lower EPC
count [22] and IMT with age and NVE [23]. Data analysis was performed using version 19 of
the SPSS statistical program and was reviewed by a biostatistician.
Results
Study population
Of the 100 consecutive AMI patients, 87 presented with STEMI and 13 with non-STEMI. Coro-
nary angiography was performed on all patients. In the STEMI group, primary percutaneous cor-
onary intervention was the revascularization method used for 66 (76%) patients, and fibrinolysis
for 15 (17%). Seven patients initially treated with fibrinolysis were subsequently treated with per-
cutaneous coronary intervention. Of the 50 patients with acute cerebrovascular disease, 35 (70%)
had a stroke diagnosis and 15 (30%) a TIA. The degree of stenosis in the symptomatic artery was
30% to 50% in 14 (34%) patients, 51% to 70% in 10 (20%), higher than 70% in 21 (42%) and
complete occlusion in 2 (4%) patients. Two patients were treated with intravenous thrombolysis
and 12 (24%) with delayed surgical or endovascular revascularization therapies.
Demographics and the clinical characteristics of the study population are shown in Table 1.
Patients with AMI were younger (53.7 vs. 64.5 years; P<0.01) and showed a lesser prevalence
of hypertension (27% vs. 68%; P< 0.01), diabetes mellitus (11% vs. 28%; P< 0.01), hypercho-
lesterolemia (20% vs. 42%; P< 0.01) and a greater prevalence of cigarette smoking (74% vs.
56%; p = 0.03) than patients with strokes. Atherosclerotic burden was higher in patients with
strokes than with AMI (36% with 3 territories vs 2%, P<0.01). Following discharge, AMI
patients were more frequently treated with aspirin (99% vs. 78%; P< 0.001), clopidogrel (95%
vs. 24%; P< 0.001), beta-blockers (85% vs. 6%; P< 0.001), and angiotensin-converting enzyme
inhibitors (63% vs. 30%, P< 0.001) or angiotensin receptor blockers (26% vs. 14%, P = 0.09)
than patients with strokes. The prescription of statins at discharge was similar among AMI and
stroke patients (100% vs. 98%; P = 0.94). Anticoagulation therapy was very infrequent and was
similar in both cohorts (8% of AMI vs 12% of strokes, P = 0.42).
EPC and baseline clinical variables
Of the 150 patients, 14 (9.3%) had basal EPC samples that were unavailable or invalid and 18
(12%) had values of 0. The median and IQR for each EPC quartile were as follows: Q1, 0.0
(0.0–38.25); Q2, 97.5 (65.22–121.15); Q3, 214.65 (185.75–239.65), Q4, 486.60 (380.62–799.80).
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Higher basal EPC was associated with lower age (p for trend = 0.076), AMI (p = 0.019), and a
lower proportion of DM (p = 0.077). Glycated haemoglobin was lower in patients with a low
EPC, although all values were within the normal range. Although not statistically significant,
patients with a higher AB had lower basal EPC. The univariate analysis is summarized in
Table 2.
CEC and baseline clinical variables
Of 150 patients included, 5 (3.3%) patients had no basal CEC data and 10 (6.7%) had a cell
count of 0. The median and IQR of each CEC quartile were as follows: Q1, 21.50 (0.0–51.75);
Q2, 113.97 (100.82–129.73); Q3, 208.30 (168.55–258.50); Q4, 570.50 (415.77–869.000). We
found no association between cardiovascular risk factors or AB and basal CEC. Basal CEC
count was higher in AMI patients (P = 0.014). A summary of the univariate analysis is found in
Table 3.
Incidence of cardiovascular events
A total of 19 patients (12.66%) had a NVE during follow-up (9/100 AMI patients and 10/50
stroke patients): 5 new strokes, 3 new TIA, 4 new AMI, 6 hospitalizations for other acute
Table 1. Bivariate analysis between AMI and stroke patients.
AMI STROKE P value
N = 100 N = 50
Age, mean (SD) y 53.7(10.2) 64.5 (9.4) <0.01
Males, n (%) 85 (85.0) 42 (84.0) 0.87
Hypertension, n (%) 27 (27.0) 34 (68.0) <0.01
Hypercholesterolemia, n (%) 20 (20.0) 21 (42.9) <0.01
Diabetes Mellitus, n (%) 11 (11.0) 14 (28.0) <0.01
Current smoking, n (%) 74 (74) 28 (56) 0.03
Previous IHD, n (%) 0 (0) 2 (4) 0.04
Previous stroke, n (%) 0(0) 0 (0)
Previous PAD, n (%) 2 (2) 2 (4) 0.474
BMI 26.6 (24.3–29.3) 28.1 (25.3–30.3) 0.117
Total Cholesterol (mg/dL) 197 (40) 199 (51) 0.80
LDL Cholesterol (mg/dL) 129 (33) 129 (39) 0.97
Triglycerides (mg/dL) 168 (135) 162 (88) 0.79
HbA1c% (median, IQR) 6.1 (1.7) 6.6 (1.6) 0.09
AB, n (%) <0.01
Three territories 2 (2) 18 (36)
Two territories 42 (42) 23 (46)
One territory 56 (56) 9 (18)
IMT>0.9, n (%) 31 (36.9) 20 (40.8) 0.65
NVE, n (%) 9 (9) 10 (20) 0.06
IHD = Ischemic heart disease
PAD = Peripheral arterial disease
BMI = Body mass index
AB = Atherosclerotic Burden
IMT = Intima media thickness
NVE = New vascular event.
doi:10.1371/journal.pone.0132415.t001
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cardiovascular diseases, and 1 cardiovascular death. All new AMI patients had had a previous
AMI and all the strokes/TIAs occurred in patients with initial stroke. Median time to NVE was
30 days (range 2–90). In univariate analysis, the incidence of NVE was associated with age (P
for trend 0.039), IMT0.9 (P = 0.044) and basal EPC count (P = 0.041). The analysis is sum-
marized in Table 4. Basal CEC count was not associated with NVE.
Regarding medication at discharge, the proportions of aspirin (79% vs 93%, P = 0.047), clo-
pidogrel (52% vs.74%, p = 0.052) and beta-blockers given (42% vs. 61%, P = 0.094) was lower
in patients who had had a NVE (Table A in S1 File).
To explore potential associations between each NVE and the study variables, we divided
NVEs into two subgroups due to the low number of events in each category: the first group
included new strokes/TIAs; and the second group, other vascular events (AMI/cardiovascular
hospitalization or death). We performed a separate bivariate analysis between vascular risk fac-
tors and each subgroup outcome. Variables associated with new stroke/TIA compared with
other vascular events were: HTA (75% vs. 9%, P = 0.014) and age (67.38 vs. 58.4, P = 0.026).
Moreover, patients who had a new stroke/TIA had lower EPC counts than patients who suf-
fered other vascular events (p = 0.027). (Table B in S1 File)
Table 2. Bivariate comparison between study variables and EPC quartiles.
BasEPC Q1 N = 34 BasEPC Q2 N = 34 BasEPC Q3 N = 34 BasEPC Q4 N = 34 P value
Age, mean (SD) y 58.65 (10.50) 59.06 (12.29) 58.38 (10.28) 52.91 (11.08) 0.076
Males, n (%) 30 (88.2) 27 (79.4) 31 (91.2) 28 (82.4) 0.504
AMI patients, n (%) 20 (58.8) 19 (55.9) 22 (64.7) 30 (88.2) 0.019
Stroke patients, n (%) 14 (41.2) 15 (44.1) 12 (35.3) 4 (11.8)
Hypertension 15 (44.1) 14 (41.2) 15 (44.1) 12 (35.3) 0.866
Hypercholesterolemia, n (%) 6 (17.6) 10 (29.4) 9 (26.5) 11 (32.4) 0.549
Diabetes Mellitus, n (%) 6 (17.6) 8 (23.5) 8 (23.5) 1 (2.9) 0.077
Current smoker, n (%) 25 (73.5) 20 (58.8) 23 (67.6) 25 (73.5) 0.517
Alcohol overuse, n (%) 8 (23.5) 6 (17.6) 7 (20.6) 2 (5.9) 0.227
BMI, med (q25-q75) 27.1(24.2–29.4) 26.6(24.4–29.8) 26.5(24.5–30.1) 27.4(25.8–29.4) 0.965
HbA1c% med (q25-75) 5.5 (5.0–5.9) 5.8 (5.6–6.7) 5.9 (5.3–7.5) 5.8 (5.4–6.0) 0.048
AB, n (%) 0.414
Three territories 7 (20.6) 4 (11.8) 6 (17.6) 1 (2.9)
Two territories 13 (38.2) 17 (50.0) 13 (38.2) 17 (50.0)
One territory 14 (41.2) 13 (38.2) 15 (44.1) 16 (47.1)
IMT>0.9, n (%) 9 (29.0) 13 (41.9) 12 (38.7) 16 (55.2) 0.229
NVE, n (%) 9 (26.5) 3 (8.8) 2 (5.9) 3 (8.8) 0.020
New stroke/TIA 6 (17.6) 2 (5.9) 0 (0.0) 0 (0.0)
New ACS 1 (2.9) 0 (0.0) 1 (2.9) 1 (2.9)
Other ACV event 2 (5.9) 1 (2.9) 1 (2.9) 2 (5.9)
BasEPC = Basal count of EPC
AMI = Acute myocardial infarction
BMI = Body mass index
AB = Atherosclerotic Burden
IMT = Intima-media thickness
NVE = New vascular event
ACS = Acute coronary syndrome
ACV = Acute cardiovascular event.
doi:10.1371/journal.pone.0132415.t002
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Multivariate Cox regression analysis showed an independent association with basal EPC.
The risk is highest in the lowest quartile (Table 5 and Fig 1). Compared with Q4, adjusted HRs
were as follows: Q1 [HR: 10.33, 95% CI (1.22–87.34), P = 0.032]; Q2 [HR: 1.43, 95%CI (0.17–
17.48) P = 0.778]; Q3 [HR: 0.67, 95% CI (0.03–11.48), P = 0.789]. IMT0.9 was also an inde-
pendent predictor of NVE [HR: 4.12, 95% CI (1.21–13.95), P = 0.023]. In the model without
IMT but adjusted for age (Table C in S1 File), sensitivity analyses showed an estimated HR of
2.96 (p = 0.105) for EPC Q4 vs Q1, whereas in the model without age but adjusted for IMT
(Table C in S1 File), the HR was 15.77 (p = 0.010). These results clearly indicate that age was
not a confounding variable when IMT was already present in the model, since the HR
remained significant and varied from 10.33 to 15.77 (Table 4). On the other hand, IMT was a
strong reverse confounding variable, even in the presence of age, since the HR varied from
10.33 to 2.96 and ceased to be significant when IMT was removed from the model.
Other variables associated in bivariate analysis, such as HbA1c or medication at discharge,
were not associated in the Cox regression analysis. (Tables D-E in S1 File)
Table 3. Bivariate comparison between study variables and CEC quartiles.
BasCEC Q1 N = 34 BasCEC Q2 N = 34 BasCEC Q3 N = 33 BasCEC Q4 N = 34 P value
Age, mean (SD) 60.14 (10.26) 58.11(9.70) 54.22 (11.72) 56.94 (12.34) 0.145
Males, n (%) 29 (80.6) 31 (86.1) 32 (86.5) 31 (86.1) 0.877
AMI patients, n (%) 17 (47.2) 23 (63.9) 29 (78.4) 28 (77.8) 0.014
Stroke patients, n (%) 19 (52.8) 13 (36.1) 8 (21.6) 8 (22.2)
Hypertension, n (%) 16 (44.4) 14 (38.9) 13 (35.1) 17 (47.2) 0.721
Hypercholesterolemia, n (%) 9 (25.0) 10 (27.8) 11 (29.7) 10 (27.8) 0.976
Diabetes Mellitus, n (%) 8 (22.2) 5 (13.9) 5 (13.5) 7 (19.4) 0.707
Current smoker, n (%) 20 (55.6) 29 (80.6) 27 (73.0) 23 (63.9) 0.117
Alcohol overuse, n (%) 6 (16.7) 10 (27.8) 4 (10.8) 4 (11.1) 0.176
BMI med (q25-75) 26.7(24.1–29.8) 26.8(24.3–29.4) 26.9(24.5–30.2) 27.5(26.1–29.6) 0.717
HbA1c%, med (q25-75) 5.8 (5.3–6.8) 5.7 (5.4–6.2) 5.8(5.4–6.4) 5.7 (5.4–6.2) 0.968
AB, n (%) 0.562
Three territories 6 (16.7) 3 (8.3) 5 (13.5) 5 (13.9)
Two territories 16 (44.4) 21 (58.3) 13 (35.1) 15 (41.7)
One territory 14 (38.9) 12 (33.3) 19 (51.4) 16 (44.4)
IMT>0.9, n (%) 13 (43.3) 12 (35.3) 12 (37.5) 14 (42.4) 0.895
NVE, n (%) 7 (19.4) 6 (16.7) 3 (8.1) 2 (5.6) 0.219
New stroke/TIA 3 (8.3) 4 (11.1) 1 (2.7) 0 (0.0)
New ACS 1 (2.8) 1 (2.8) 2 (5.4) 1 (2.8)
Other ACV event 3 (8.3) 1 (2.8) 3 (8.1) 1 (2.8)
BasCEC = Basal count of circulating endothelial cells
AMI = Acute myocardial infarction
BMI = Body mass index
AB = Atherosclerotic Burden
IMT = Intima media thickness
NVE = New vascular event
ACS = Acute coronary syndrome
ACV = Acute cardiovascular event.
doi:10.1371/journal.pone.0132415.t003
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Discussion
Our study is the first to show that basal EPC, but not basal CEC count, is associated with
6-month NVE in patients with AMI and AS. Cerebrovascular diseases and CAD are the highest
causes of mortality worldwide. However, whereas CAD is usually attributable to large-vessel
atherosclerosis, stroke has a far more heterogeneous pathophysiology, including emboli
Table 4. Bivariate analysis between study variables and NVE.
Vascular events yes N = 19 Vascular events No N = 131 P value
Age, mean (SD) 62.21 (9.74) 56.58 (11.17) 0.039
Males, n (%) 15 (78.9) 112 (85.5) 0.443
Hypertension, n (%) 7 (36.8) 54 (41.2) 0.758
Hypercholesterolemia, n (%) 6 (31.6) 35 (26.7) 0.653
Diabetes Mellitus, n (%) 4 (21.1) 21 (16) 0.587
Current smoker, n (%) 14 (73.7) 88 (67.2) 0.260
BMI, med (q25-75) 25.8 (23.7–19.4) 26.9 (24.8–29.7) 0.384
Atherosclerotic Burden, n (%) 0.205
Three territories 5 (26.3) 15 (11.5)
Two territories 7 (36.8) 58 (44.3)
One territory 7 (36.8) 58 (44.3)
IMT>0.9, n (%) 9 (64.3) 42 (35.3) 0.044
Basal EPC, n (%) 0.041
Q1 9 (52.9) 25 (21.0)
Q2 3 (17.6) 31 (26.1)
Q3 2 (11.8) 32 (26.9)
Q4 3 (17.6) 31 (26.1)
Basal CEC, n (%) 0.219
Q1 7 (38.9) 29 (22.8)
Q2 6 (33.3) 30 (23.6)
Q3 3 (16.7) 34 (26.8)
Q4 2 (11.1) 34 (26.8)
BMI = Body mass index
IMT = Intima-media thickness
EPC = Endothelial progenitor cells
CEC = Circulating endothelial cells.
doi:10.1371/journal.pone.0132415.t004
Table 5. Cox regression analysis for the risk of NVE.
HR 95% CI P
Basal EPC quartiles 0.003
Basal EPC Q1 10.33 (1.22–87.34) 0.032
Basal EPC Q2 1.43 (0.17–17.48) 0.778
Basal EPC Q3 0.67 (0.03–11.48) 0.786
IMT > 0.9 4.12 (1.21–13.95) 0.023
Age 1.05 (0.98–1.12) 0.118
EPC = Endothelial progenitor cells
IMT = Intima-media thickness.
doi:10.1371/journal.pone.0132415.t005
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originating from the heart, cerebral small-vessel disease (lacunar infarcts), and an abundant
variety of other less frequent causes.
Atherothrombotic strokes—the most prevalent stroke subtype [24]—are those caused by
large-vessel atherosclerosis in the major blood vessels supplying the brain, such as the carotid,
vertebral, and basilar arteries or the vessels forming the circle of Willis. This stroke subtype
and AMI not only share a common pathophysiology (large-vessel atherosclerosis) but also a
high (20%) 10-year risk of future cardiovascular events [15,16].
Although very promising results have been found in trials using stem cell therapy in vascu-
lar diseases [25,26], the role of circulating EPC and CEC is not completely understood. The
PROCELL study aimed to study the role of these cells in patients with AMI and acute AS.
We found that patients with a very low EPC count have a higher risk of a NVE during the
first 6 months. These results come as no surprise in AMI patients since previous studies have
found similar results. In a large study including 519 patients undergoing coronary angiography
[27], decreasing levels of baseline EPC were associated with death from cardiovascular causes,
first major cardiovascular events, revascularization and hospitalization after 12 months of fol-
low-up, although EPCs were not associated with AMI or stroke. That study included patients
Fig 1. Kaplan-Meier survival curve according to EPC quartiles.
doi:10.1371/journal.pone.0132415.g001
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with acute, subacute and chronic myocardial infarction and the incidence of AMI or stroke
during follow-up was less than in our study (6.7% and 3.4% respectively). There was also no
information about stroke subtype (ischemic or haemorrhagic). Another study including 44
patients with stable CAD, 33 patients with acute coronary syndrome and 43 control subjects
also found an independent association with EPC and later cardiovascular events during a
median follow-up of 10 months [13]. Eleven patients (14.5%) had a cardiovascular event, but
most of these were revascularizations
In addition, a lower EPC count has been associated with NVEs in healthy subjects [28] and
patients with kidney disease [29] or metabolic syndrome [30]. However, in most of these stud-
ies, a new stroke was not considered an outcome.
There are numerous differences between these studies and ours: We included only patients
with acute diseases (AMI and stroke) because these patients are at a high risk of subsequent
cardiovascular events. [31] For this reason, we studied patients admitted within the first 24h
after the initial event and the follow-up was shorter. It is worthy of note that, in our study, 6 of
19 patients (31.57%) had the NVE in the first week of follow-up, pointing out the importance
of studying acute patients. Furthermore, we studied ischemic strokes that had the same etiol-
ogy, large artery atherosclerosis, whereas in the previous studies, the stroke etiologies were
mixed; this is a crucial matter, especially when studying pathophysiology. We did not include
programmed revascularization as an outcome because we focused only on the risk of unex-
pected acute cardiovascular events. We included ischemic stroke as an outcome, whereas other
studies did not. Finally, our study is the first to consider EPC and CEC counts in the same
cohort.
In addition, to the best of our knowledge, the association between NVE and basal EPC
count has not previously been described in stroke patients. Only one study [14] found an asso-
ciation between lower basal EPC and a combination of NVE and poor neurological status at 90
days, with only 3 out of 138 patients having a stroke recurrence.
Several experimental studies have proved that circulating EPC is capable of mobilizing to
injured arteries and repairing the endothelium [32]. In our study, we also observed the poten-
tial protective effect of these cells as a marker of a high risk of vascular events even in patients
receiving the best medical treatment available.
Although the role of EPC has been broadly studied, the influence of CEC on the risk of
NVE has received little attention. The association between CEC and NVE in patients with
ischemic stroke has not been previously reported, and we found only one previous study of
patients with acute coronary syndrome in which 48h CEC was the only independent predictor
of a major cardiovascular event at one year [33]. We were unable to replicate these findings;
this was probably due to methodological differences between the studies, most importantly
that the CEC characterization was different (CD 146+CD31- in the study cited and CD146
+CD31+ in our study) and also that strokes were not included as a vascular outcome in the ear-
lier study.
Apart from the cell analysis, we aimed to identify other clinical variables with a predictive
role in vascular risk. We found that carotid IMT0.9 was independently associated with the
risk of NVE. Increased carotid IMT has been considered an early marker of atherosclerosis and
a proven risk factor for future vascular events in healthy populations, as well as in patients with
cardiovascular disease, independently of other vascular risk factors [23,34]. In our study,
IMT0.9 was more informative than other clinical variables such as age, vascular risk factors,
or atherosclerotic burden. This is important because, although various meta-analyses found
that IMT measurement adds little predictive value in the general population [35,36], it can help
identify subgroups with a worse prognosis in patients at high vascular risk, such as AMI or AS
patients.
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Our study has several strengths. We have uniformly studied patients with different acute
manifestations of a common disease, large-vessel atherosclerosis. All patients underwent
exhaustive vascular study and were treated under current international guidelines. All samples
were collected within the first 24h of the ischemic event in order to study early recurrences.
Finally, this was the first study to analyse both cell subtypes at the same time. The study also
has a few limitations, the most important being the small sample size. However it should be
pointed out that the PROCELL study was a prospective, multicenter case-control study that
included a highly selected population. Patients were studied during the acute phase and the fol-
low-up was very thorough [18]. In addition, the results of the study are in agreement with pre-
vious studies with similar methodologies and similar sample sizes. [13,14,33] We consider
therefore that although the small sample size prevented a more detailed analysis of patient sub-
types and vascular events, it does not invalidate the association between EPC and NVE. Sec-
ondly, although the information on the patients recruited was extensive, we did not include
other comorbidities that may have influenced the association between EPC and the risk of
NVE, such as obstructive sleep apnea, which is implicated in the development of hypertension,
endothelial dysfunction and higher intima-media thickness, all elements known to lead to ath-
erosclerosis. [37] Lastly, although the medication prescribed and patient compliance was veri-
fied at every visit, due to the observational nature of the study and the study size, the influence
of drugs on the risk of vascular events could not be ascertained.
Conclusions
In patients with acute manifestations of large-vessel atherosclerosis, such as AMI or AS, a low
EPC count is a strong predictor of future vascular events, whereas CEC count has no predictive
role. More research on this field is needed to confirm the protective role of EPC in patients
with vascular disease.
Supporting Information
S1 File. Table A. Bivariate analysis of medication at discharge and the risk of new vascular
events. Table B. Bivariate analysis of study variables and subtypes of NVE. Table C. Model A.
Sensitivity analysis: Cox regression model after removal of IMT. Model B. Cox regression
model after removal of age. Table D. Cox regression analysis including HbA1c. Table E. Cox
regression analysis including aspirin.
(DOCX)
Acknowledgments
Isaac Subirana, MSc, Epidemiology and Cardiovascular Genetics, Inflammatory and Cardio-
vascular Disorders Research Program (IMIM) reviewed the statistical analysis. Elaine M. Lilly,
PhD, Writers First Aid, provided assistance in the English translation and copyediting of the
manuscript.
In memoriam
In memory of Magda Heras i Fortuny MD, PhD (1953–2014)
Author Contributions
Conceived and designed the experiments: GE JMMAV CH JS MH JR. Performed the experi-
ments: EC AR JNMD SN. Analyzed the data: EC AR A. Oliveras. Contributed reagents/materi-
als/analysis tools: EC A. Ois EG. Wrote the paper: EC AR.
Endothelial Progenitor Cells and Vascular Events
PLOS ONE | DOI:10.1371/journal.pone.0132415 September 2, 2015 11 / 13
References
1. Rafii S, Meeus S, Dias S, Hattori K, Heissig B, Shmelkov S, et al. Contribution of marrow-derived pro-
genitors to vascular and cardiac regeneration. Semin Cell Dev Biol. 2002; 13(1):61–7. PMID: 11969372
2. Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, Carothers J. Bone marrow as a source of
endothelial cells and NeuN-expressing cells after stroke. Stroke. 2002; 33(5):1362–8. PMID: 11988616
3. Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Ribó M, Alvarez-Sabín J, et al.
Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after
ischemic stroke. Microvasc Res. 2010; 80(3):317–23. doi: 10.1016/j.mvr.2010.05.008 PMID: 20594997
4. Boos CJ, Lip GYH, Blann AD. Circulating Endothelial Cells in Cardiovascular Disease. Journal of the
American College of Cardiology. 2006. p. 1538–47.
5. Makin AJ, Blann AD, Chung NAY, Silverman SH, Lip GYH. Assessment of endothelial damage in ath-
erosclerotic vascular disease by quantification of circulating endothelial cells: Relationship with von
Willebrand factor and tissue factor. Eur Heart J. 2004; 25(5):371–6. PMID: 15033248
6. Nadar SK, Lip GYH, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb
Haemost. 2005; 94(4):707–12. PMID: 16270621
7. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, et al. Mobilization of endothelial progeni-
tor cells in patients with acute myocardial infarction. Circulation. 2001.
8. McClung JA, Naseer N, SaleemM, Rossi GP, Weiss MB, Abraham NG, et al. Circulating endothelial
cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c. Diabetologia. 2005;
48(2):345–50. PMID: 15660261
9. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of athero-
sclerosis. Atherosclerosis. 2007. p. 46–54. PMID: 17493626
10. Umemura T, Soga J, Hidaka T, Takemoto H, Nakamura S, Jitsuiki D, et al. Aging and hypertension are
independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens.
2008; 21(11):1203–9. doi: 10.1038/ajh.2008.278 PMID: 18787520
11. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothe-
lial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001.
12. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor
cells and cardiovascular outcomes. N Engl J Med. 2005; 353(10):999–1007. PMID: 16148285
13. Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, et al. Reduced number of
circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the
clinical importance of endogenous vascular repair. Circulation. 2005; 111(22):2981–7. PMID:
15927972
14. Yip H-K, Chang L-T, ChangW-N, Lu C-H, Liou C-W, Lan M-Y, et al. Level and value of circulating endo-
thelial progenitor cells in patients after acute ischemic stroke. Stroke. 2008; 39(1):69–74. PMID:
18063830
15. Ois A, Cuadrado-Godia E, Rodríguez-Campello A, Giralt-Steinhauer E, Jiménez-Conde J, Lopez-
Cuiña M, et al. Relevance of stroke subtype in vascular risk prediction. Neurology. 2013; 81(6):575–80.
doi: 10.1212/WNL.0b013e31829e6f37 PMID: 23825174
16. Lackland DT, Elkind MS V, D’Agostino R, Dhamoon MS, Goff DC, Higashida RT, et al. Inclusion of
stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the
American Heart Association/American Stroke Association. Stroke. 2012; 43(7):1998–2027. doi: 10.
1161/STR.0b013e31825bcdac PMID: 22627990
17. Grau M, Subirana I, Elosua R, Solanas P, Ramos R, Masiá R, et al. Trends in cardiovascular risk factor
prevalence (1995-2000-2005) in northeastern Spain. Eur J Cardiovasc Prev Rehabil. 2007; 14(5):653–
9. PMID: 17925624
18. Regueiro A, Cuadrado-Godia E, Bueno-Betí C, Diaz-Ricart M, Oliveras A, Novella S, et al. Mobilization
of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after
acute myocardial infarction and stroke. J Mol Cell Cardiol 2015; 80:146–55. doi: 10.1016/j.yjmcc.2015.
01.005 PMID: 25619946
19. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative clas-
sification system for acute ischemic stroke. Ann Neurol. 2005; 58(5):688–97. PMID: 16240340
20. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, et al. Mannheim intima-
media thickness consensus. Cerebrovascular Diseases. 2004. p. 346–9.
21. Roquer J, Ois A, Rodriguez-Campello A, Gomis M, Munteis E, Jimenez-Conde J, et al. Atherosclerotic
burden and early mortality in acute ischemic stroke. Arch Neurol. 2007; 64:699–704. PMID: 17502469
22. Williamson K, Stringer SE, Alexander MY. Endothelial progenitor cells enter the aging arena. Front Phy-
siol. 2012; 3:1–7.
Endothelial Progenitor Cells and Vascular Events
PLOS ONE | DOI:10.1371/journal.pone.0132415 September 2, 2015 12 / 13
23. Roquer J, Segura T, Serena J, Cuadrado-Godia E, Blanco M, García-García J, et al. Value of carotid
intima-media thickness and significant carotid stenosis as markers of stroke recurrence. Stroke. 2011;
42(11):3099–104. doi: 10.1161/STROKEAHA.110.612010 PMID: 21852617
24. Arenillas JF. Intracranial atherosclerosis: Current concepts. Stroke. 2011; 42 (Suppl 1): S20–3
25. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, et al. Transcoronary
transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006; 355(12):1222–32.
PMID: 16990385
26. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angio-
genesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot
study and a randomised controlled trial. Lancet. 2002; 360(9331):427–35. PMID: 12241713
27. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating Endothelial Progenitor
Cells and Cardiovascular Outcomes. 2005;999–1007.
28. Hill JM, Zalos G, Halcox JPJ, SchenkeWH,WaclawiwMA, Quyyumi AA, et al. Circulating endothelial
progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593–600.
PMID: 12584367
29. Lorenzen J, David S, Bahlmann FH, de Groot K, Bahlmann E, Kielstein JT, et al. Endothelial progenitor
cells and cardiovascular events in patients with chronic kidney disease—a prospective follow-up study.
PLoS One. 2010 Jan; 5(7):e11477. doi: 10.1371/journal.pone.0011477 PMID: 20628606
30. Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, Dimmeler S, et al. Low CD34+ cell
count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis.
2009; 207(1):213–9. doi: 10.1016/j.atherosclerosis.2009.03.040 PMID: 19406403
31. Steg PG, Bhatt DL, Wilson PWF, D’Agostino RS, Ohman EM, Rother J, et al. One-year cardiovascular
event rates in outpatients with atherothrombosis. JAMA. United States; 2007 Mar; 297(11):1197–206.
PMID: 17374814
32. Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. Therapeutic potential of endothelial progenitor
cells in cardiovascular diseases. Hypertension. 2005. p. 7–18. PMID: 15956118
33. Lee KW, Lip GYH, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, vonWillebrand fac-
tor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood. 2005; 105(2):526–
32. PMID: 15374879
34. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness
and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997; 96(5):1432–7.
PMID: 9315528
35. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen TP, et al. Carotid intima-media
thickness progression to predict cardiovascular events in the general population (the PROG-IMT col-
laborative project): A meta-analysis of individual participant data. Lancet. 2012; 379(9831):2053–62.
doi: 10.1016/S0140-6736(12)60441-3 PMID: 22541275
36. Den Ruijter HM, Peters SAE, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al. Common
carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA
[Internet]. American Medical Association; 2012; 308(8):796–803. doi: 10.1001/jama.2012.9630 PMID:
22910757
37. Ciccone MM, Scicchitano P, Mitacchione G, Zito A, Gesualdo M, Caputo P, et al. Is there a correlation
between OSAS duration/severity and carotid intima-media thickness? Respir Med. England; 2012
May; 106(5):740–6.
Endothelial Progenitor Cells and Vascular Events
PLOS ONE | DOI:10.1371/journal.pone.0132415 September 2, 2015 13 / 13
